uniQure (QURE) Work In Process (2022 - 2024)

uniQure (QURE) posted quarterly Work In Process of $1.3 million for Q1 2024, down 67.36% quarter-over-quarter from $4.1 million in Q4 2023.

uniQure (QURE) Work In Process (2022 - 2024) Analysis & Trends

uniQure's Work In Process history runs 3 years deep, the most recent figure standing at $1.3 million for Q1 2024.

  • In Q1 2024, Work In Process changed N/A year-over-year to $1.3 million; the TTM figure through Mar 2024 stood at $1.3 million (changed N/A YoY), while the FY2023 annual figure was $4.1 million, up 119.26% from the prior year.
  • Work In Process for Q1 2024 stood at $1.3 million, down from $4.1 million in the prior quarter.
  • The five-year high for Work In Process was $6.6 million in Q3 2023, with the low at $1.3 million in Q1 2024.
  • The 3-year median for Work In Process is $3.1 million (2022), against an average of $3.4 million.
  • Peak annual rise in Work In Process reached 202.89% in 2023, while the deepest fall reached 119.26% in 2023.
  • uniQure's Work In Process stood at $1.9 million in 2022, then soared by 119.26% to $4.1 million in 2023, then plunged by 67.36% to $1.3 million in 2024.
  • Business Quant data shows QURE's Work In Process at $1.3 million in Q1 2024, $4.1 million in Q4 2023, and $6.6 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 uniQure 3.37 Bn 3.37 Bn 5.49 Mn

Historic Data

Download Data
DateValue
Mar 31, 2024 1.34 Mn
Dec 31, 2023 4.11 Mn
Sep 30, 2023 6.60 Mn
Jun 30, 2023 4.06 Mn
Dec 31, 2022 1.87 Mn
Sep 30, 2022 2.18 Mn